TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Nimotuzumab in Combination With Radiation Therapy in Patients With Brain Metastases

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Providing a written informed consent (see Appendix A);~* Age ≥18 years;~* Histologic or cytologic confirmed diagnosis of NSCLC of any epithelial type (squamous, adenocarcinoma, large cell, or other);~* At least one newly diagnosed measurable metastatic lesion from NSCLC in the brain;~* Patient had initial diagnosis of brain metastases by image, within 8 weeks of registration~* KPS ≥70;~* Absolute neutrophil count ≥ 1500/mm³;~* Platelet count ≥ 50,000/mm³;~* Serum creatinine ≤2.0 mg/dL;~* Serum transaminases ≤2 x the upper limit of normal (ULN);~* Total serum bilirubin ≤2 x ULN;~* And a lactate dehydrogenase (LDH) level ≤1.3 x ULN.~Exclusion Criteria:~* Pregnancy, lactation or parturition within the previous 30 days (fertile female or male patients should practice contraception);~* Prior WBRT, brain metastases resection with no other measurable lesion remaining;~* Extracranial metastases in two or more organs;~* Known leptomeningeal or subarachnoid tumor spread;~* Plan to use radiosurgery or radiation boost after completion of WBRT;~* Plan to use chemotherapy or any other systemic antineoplastic modality during WBRT;~* Previous use of an anti-EGFR drug;~* Participation in another ongoing therapeutic trial;~* Presence of known HIV seropositivity, severe comorbidities, or other malignant neoplasm within 5 years (except adequately treated basal- or squamous-cell carcinoma of skin or in situ carcinoma of the uterine cervix);~* Hypersensitivity or allergy to any of the drugs to be administered in this study;~* Inability or unwillingness to complete the required assessments;~* Geographic inaccessibility for treatment or follow-up evaluations.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Nimotuzumab (200 mg fixed dose) will be administered by the intravenous route weekly during WBRT and following WBRT. Radiotherapy will consist of 30 Gy, in 10 fractions of 3 Gy/day.
- 2 (Type: PLACEBO_COMPARATOR): A placebo will be administered by the intravenous route weekly during WBRT and following WBRT.~Radiotherapy will consist of 30 Gy, in 10 fractions of 3 Gy/day.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Technology Delivered Diabetes-Modified Behavioral Activation Treatment

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: FACTORIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Age ≥21 years~* Clinical diagnosis of T2DM and HbA1c ≥8% at the screening visit;~* Self-identified as AA~* Subject must be willing to use the FORA monitoring system for 6 months~* Subject must be willing to use the study assigned smartphone including videoconferencing, lifestyle monitoring and medication monitoring apps for 6 months~* Subjects must be able to communicate in English~* Subjects must have access to a landline or Ethernet for FORA data uploads for the study period.~Exclusion Criteria:~* Mental confusion on interview suggesting significant dementia~* Participation in other diabetes clinical trials~* Alcohol or drug abuse/dependency~* Active psychosis or acute mental disorder~* Life expectancy \<6 months.

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Group 1 (Type: OTHER): Arm: Other: Group 1 Participants in this group will receive the culturally tailored education booklet titled Your Guide to Sugar Diabetes. In addition, subjects will complete 10 sessions of diabetes education delivered weekly via videoconferencing lasting 60 minutes each session as detailed above.
- Group 2 (Type: ACTIVE_COMPARATOR): Arm: Active Comparator: Group 2 Participants in this group will receive as detailed above, the culturally tailored education booklet titled My Guide to Sugar Diabetes. In addition, subjects will complete 10 sessions of diabetes education delivered weekly via videoconferencing lasting 60 minutes each session. Patients will also be assigned the FORA Test-n-Go Series Blood Glucose and Blood Pressure monitors and provided glucose test strips to allow testing at least once a day during the initial face-to-face session.
- Group 3 (Type: EXPERIMENTAL): Arm: Experimental: Group 3 The intervention has 3 components: 1) diabetes education; 2) home telemonitoring; and 3) diabetes modified behavioral activation, delivered by nurses via smartphones. Trained nurses will deliver the TECH DM-BAT intervention via videoconferencing technology on smartphones.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Use of Daclizumab for the Prevention of Allograft Rejection in Pediatric Heart Transplant Patients

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients must be undergoing their first cardiac allograft transplant.~* Male or female must be less than or equal to 18 years of age.~* Women of childbearing potential must have a negative serum pregnancy test within 48 hours prior to transplantation. The sensitivity must be equal to at least 50 mIU/ml. (Urine test is allowed in addition to serum test in patients where serum results are delayed.)~* Women of childbearing potential must use two reliable forms of contraception simultaneously.~* Effective contraception must be used before beginning study drug therapy, and for 4 months following discontinuation of study drug therapy.~* Patients and/or their guardians must be willing and be capable of understanding the purpose and risks of the study and must sign a statement of informed consent.~Exclusion Criteria:~* Patients with a history of hypersensitivity reactions to any of the constituents of the Zenapax(R) preparation or having had hypersensitivity reactions to human or murine immune globulin preparations in the past.~* Women lactating, pregnant or of childbearing potential not using, or who are unwilling to use two reliable forms of contraception simultaneously during the study~* History of a psychological illness or condition which would interfere with the patient's ability to understand the requirements of the study~* White blood count \< 2500/mm\^3, platelets \< 50,000 /mm\^3 or hemoglobin \< 6 g/dL.~* HIV-1 infection or the presence of positive hepatitis B surface antigen (HBsAg) or chronic hepatitis C.~* Active peptic ulcer disease~* Severe diarrhea or other gastrointestinal disorders which might interfere with the ability to absorb oral medication~* Malignancies within the past 5 years, excluding skin carcinomas (basal or squamous cell) that have been adequately treated~* Patients who have received within the past 30 days or require concomitant treatment with other investigational drugs or immunosuppressive medications that are prohibited for this study~* Inability to start microemulsion form of cyclosporine within 72 hours

- Gender: ALL
- Minimum Age: 1 Month
- Maximum Age: 18 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: The Use of Prophylactic Hemoclips in the Endoscopic Resection of Large Pedunculated Polyps

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with one or more pedunculated polyps, the heads of which measured more than 1cm (regardless of the stalk thickness and length), and they were compared against the size of the biopsy forceps (6mm) and subsequently confirmed in the anatomical specimen~* Not to have any hemostatic alterations at the time the endoscopy was performed (confirmed by the usual blood tests taken before the procedure).~Exclusion Criteria:~* Patients younger than 18 years of age~* Patients with a platelet count of less than 50000, INR larger than 1.5~* Patients who refused to give their informed consent.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Hemoclip (Type: ACTIVE_COMPARATOR): In group HEMOCLIP, one or more clips were placed (based on the criteria of the endoscopist in accordance with the size of the pedicle), and the polyp was subsequently resected using a diathermy loop
- Conventional Polipectomy (Type: ACTIVE_COMPARATOR): In group CONVENTIONAL POLYPECTOMY, a conventional polypectomy was performed, which was not aided beforehand by any other hemostatic technique

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety Study of Drugs for Treatment of Visceral Leishmaniasis in Brazil

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* patients with visceral leishmaniasis characterized by fever plus hepatomegaly or splenomegaly with at least one positive result in the following laboratory tests:~* direct observation of leishmania amastigotes in bone marrow smear~* leishmania in vitro culture from bone marrow aspirates~* leishmania kDNA amplification by PCR in bone marrow or peripheral blood samples~* rK39 immunochromatographic rapid test performed on serum sample~Exclusion Criteria:~* pregnancy~* HIV infection~* chronic diseases such as diabetes mellitus,kidney, liver or cardiac diseases, schistosomiasis, malaria or tuberculosis~* immune disorders or use of drugs which interferes with the immune response~* treatment with drugs with increased risk for toxicity associated with the study drugs~* exposure to antileishmanial drugs during the past six months~* I.V. drug users~* episodes of visceral leishmaniasis relapse~* hypersensibility to the study drugs~* difficulties for accomplishing the follow-up schedule~* any of the following clinical signs of laboratory abnormalities: hepatic encephalopathy, generalized edema, toxemic individuals, severe malnutrition, jaundice, abnormal serum creatinine, bilirubin, INR \> 2,0, platelet count \< 20000/mm3

- Gender: ALL
- Minimum Age: 6 Months
- Maximum Age: 50 Years
- Healthy Volunteers: f

Study Arms:
- Meglumine antimoniate (Type: ACTIVE_COMPARATOR): Antimoniate of N-methylglucamine 20mg/kg/d, I.V. for 20 consecutive days.
- Liposomal Amphotericin B (Type: EXPERIMENTAL): Liposomal amphotericin B 3mg/kg/d I.V. for 7 consecutive days.
- Amphotericin B (Type: EXPERIMENTAL): Amphotericin B deoxycholate 1mg/kg/d I.V. for 14 consecutive days. This arm was suspended in September 19th, 2012, because of a relevant excess of adverse events and serious adverse events associated with this experimental intervention in comparison with the active comparator and the other two experimental arms. The suspension of this study arm was supported by a DSMB statement.
- Combination therapy (Type: EXPERIMENTAL): Liposomal amphotericin B 10mg/kg/d, I.V. single dose on day 0 plus Antimoniate of N-methylglucamine 20mg/kg/d for 10 consecutive days on days 1 to 10.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Penicillin Therapeutic Drug Monitoring in the Treatment of Infectious Syphilis.

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~Participants must meet all of the following criteria to be considered eligible for entry into the study:~1. At least 18 years of age~2. Presenting with clinical signs of either primary or secondary syphilis; or with early latent syphilis and documented negative serology within the past 12 months.~3. Positive syphilis serology (reactive CMIA and TP-PA) with a defined RPR titer at the time of diagnosis and enrolment~4. Able to provide informed consent~5. Able to communicate in either English of French~6. Able to return for follow-up~Exclusion Criteria:~Participants are not eligible to participate in the study if any of the following conditions are met:~1. Diagnosis of late latent syphilis, tertiary syphilis, or syphilis of unknown duration~2. Allergy to penicillin~3. Diagnosis of neurosyphilis requiring treatment with intravenous penicillin~4. Treatment with doxycycline or ceftriaxone~5. Treatment with more than one intramuscular dose of benzathine penicillin G~6. Treatment with any antibiotics within the 6 weeks prior to enrolment~7. Pregnant or breastfeeding~8. Any immune modulating therapy~9. Patient is unable or unwilling to return for blood sampling at 3 and 7 days post treatment

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Syphilis Patients (Type: None): Individuals presenting for treatment of primary, secondary or early latent syphilis at the Ottawa Hospital Immunodeficiency Clinic, the Ottawa Sexual Health Clinic or its satellite GayZone, the Montreal Chest Institute Immunodeficiency Clinic, or the Toronto General Immunodeficiency Clinic will be invited by their attending health care worker to participate in this study. Only patients presenting for and requiring treatment of infectious syphilis will be asked to participate.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Ultraviolet (UVA and UVB) Light Therapy in the Treatment of Inflammatory Skin Conditions

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Ages: 10-80 years~* Clinical diagnosis of inflammatory dermatoses such as atopic dermatitis, psoriasis, mycosis fungoides, alopecia areata, and urticaria.~* No disease states or physical conditions that would impair evaluation of the test site.~* Willing and able to receive UVA1 or UVB, as directed in the protocol; make evaluation visits; and follow protocol restrictions.~* Signed, written, witnessed, informed consent form.~* Must live within a reasonable driving distance of Ann Arbor, Michigan, and/or be able to attend all of the scheduled appointments during the study.~Exclusion Criteria:~* History of photosensitivity (development of hives or bumps with exposure to light).~* UVA1 or UVB irradiation hypersensitivity in a UVA1/UVB photo-provocation test.~* Pregnant or nursing women.~* Involved in an investigational study within the previous 4 weeks.~* Presence of bacterial superinfection.~* Taken oral therapy for skin condition within the last 4 weeks~* Topical steroid therapy within the last 2 weeks~* History of excessive scar formation or keloids

- Gender: ALL
- Minimum Age: 10 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- UVA1 Irradiation (Type: EXPERIMENTAL): UVA 1 Irradiation (Sellemed UVA1 light source) up to 130 J/cm2
- UVB Irridiation (Type: EXPERIMENTAL): UVB Irradiation maximum dose of 4000 mJ/cm2

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: METHOD - Bone Marrow Derived Mononuclear Cells in Chronic Ischemic Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Chronic cardiac ischemic disease at least 4 months after one ore more myocardial infarctions in a stable phase of the disease without option for revascularization~* LVEF at echocardiography ≤ 40%~* Significant regional LV wall motion dysfunction in the infarct related territory~* Symptoms NYHA II-IV or CCS II-III (at least class III according to one of the two classifications)~* Patient agrees to comply with all follow-up evaluations~* Age \> 18 years old~* Patient has been informed of the nature of the clinical trial and agrees to its provision and has provided written informed consent~Exclusion Criteria:~* Abnormal regional wall motion outside the infarct region~* Need for revascularization in a non infarct-related coronary within 6 months~* Patient has moderate to severe aortic valve disease, aortic or mitral prosthetic valve~* Patient has a significant mitral valve insufficiency (Effective Regurgitant office - ERO - \> 0.2 cm2 with possibility of mitral valve surgery~* Left ventricular thrombus at echocardiography~* LV-aneurysma planned surgical aneurysmectomy~* LV-wall thickness \< 5mm in the target territory~* Congenital heart disorder of hemodynamic relevance~* Known active infection or chronic infection with HIV, HBV or HCV~* Chronic inflammatory disease~* Serious concomitant disease with a life expectancy of less than one year~* Follow up impossible (no fixed abode, etc)~* Contraindication for cardiac MRI (i.e. pace maker, neurostimulator, claustrophobia)~* Severe renal failure (creatinine \> 250 mmol/l)~* Relevant liver disease (GOT \> 2x norm or spontaneous INR \> 1,5)~* Anemia (Hb \< 8.5 mg/dl), Thrombocytopenia (\< 100.000/µl)~* Women of child bearing potential or pregnancy~* Participation at a clinical trial in the last 30 days

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Intramyocardial injection of BM cells (Type: EXPERIMENTAL): None
- Intramyocardial / intracoronary injection of BM cells (Type: EXPERIMENTAL): None
- control (Type: OTHER): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Etoricoxib in Acute Soft Tissue Rheumatism Affecting the Shoulder

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Shoulder pain of acute onset of non-traumatic origin (less than 5 days).~* A history of painless unrestricted motion of the affected joint immediately before the acute attack.~* Acute one-sided shoulder pain caused by soft tissue rheumatism affecting the shoulder (bicipital tendinitis, rotator cuff tendinitis or subacromial bursitis) diagnosed by clinical signs and symptoms and confirmed by ultrasound evaluation.~* Patient-assessed pain on active movement exceeding 50 mm on a 100-mm visual analogue scale.~* Symptoms requiring therapy with NSAIDs.~Exclusion Criteria:~* Active or recurrent peptic (gastric or duodenal) ulcer.~* History of peptic ulcer or gastrointestinal bleeding.~* History of other bleeding disorders other than gastro-intestinal (e.g. cerebrovascular).~* Concomitant treatment with anti-coagulants (including heparin, ticlopidine, etc.), lithium, other NSAIDs (including aspirin doses \> 150 mg) or corticosteroids.~* Local injections of steroids in the affecting shoulder (within six months prior to the trial and during the trial).~* Presence of any form of crystal arthropathy (e.g. gout, pseudogout), destructive arthropathies (e.g. Charcot joints), infectious arthritis, chronic sepsis, osteonecrosis, rheumatoid inflammatory disease, previous~* shoulder surgery in the affected side, adhesive capsulitis in the affected side or cervical radiculopathy.~* Severe renal, cardiac or hepatic failure.~* Uncontrolled hypertension.~* Pregnancy or breast feeding.~* Confined to bed.~* Planned hospital stays or surgical procedures during the trial.~* Planned surgical intervention of the affected shoulder during the trial.~* Known alcohol or drug abuse.~* Inability to comply with the protocol.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): Etoricoxib 60 mg per oz for 14 days
- 2 (Type: ACTIVE_COMPARATOR): Etoricoxib 90 mg per oz for 14 days

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Pilot Examination of a Telehealth, Cognitive-behavioral Therapy for Adolescents

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* 14-17 years of age~* endorsement of perceived burdensomeness (score of greater than 3 on the Interpersonal Needs Questionnaire)~* emotional/behavioral problems broadly defined (Pediatric Symptom Checklist score greater than 14)~* The family being under-resourced (i.e., family is below the US census poverty line; family is receiving economic or medical government aid; child is receiving reduced fee lunch; or primary caregiver is currently unemployed) or living in an under-resourced community (i.e., majority of households in the family's census block lives under the poverty line).~Exclusion Criteria:~* Current need for acute psychiatric care (e.g., inpatient hospitalization)~* autism spectrum disorder~* psychosis~* other condition(s) related to pronounced cognitive impairment (i.e., marked impairment that precludes completion of questionnaires, verbal communication)~* Wards of the state

- Gender: ALL
- Minimum Age: 14 Years
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- Give to Others Module (Type: EXPERIMENTAL): A brief, talk therapy protocol that targets negative interpersonal beliefs (i.e., perceived social disconnection, burdensomeness) using cognitive-behavioral strategies.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility